Inventiva S.A (IVA) - Total Liabilities

Latest as of June 2025: €187.87 Million EUR ≈ $219.64 Million USD

Based on the latest financial reports, Inventiva S.A (IVA) has total liabilities worth €187.87 Million EUR (≈ $219.64 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IVA cash generation efficiency to assess how effectively this company generates cash.

Inventiva S.A - Total Liabilities Trend (2013–2024)

This chart illustrates how Inventiva S.A's total liabilities have evolved over time, based on quarterly financial data. Check Inventiva S.A (IVA) asset resilience to evaluate the company's liquid asset resilience ratio.

Inventiva S.A Competitors by Total Liabilities

The table below lists competitors of Inventiva S.A ranked by their total liabilities.

Company Country Total Liabilities
InMode Ltd
NASDAQ:INMD
USA $83.23 Million
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
China CN¥3.92 Billion
Tianjin Tianyao Pharmaceuticals Co Ltd
SHG:600488
China CN¥1.85 Billion
Hana Microelectronics Public Company Limited
BK:HANA
Thailand ฿4.84 Billion
Sedlmayr Grund und Immobilien AG
F:SPB
Germany €952.13 Million
INVEX Controladora S.A.B. de C.V
MX:INVEXA
Mexico MX$201.87 Billion
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
China CN¥124.40 Million
Horizon Bancorp
NASDAQ:HBNC
USA $5.75 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Inventiva S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Inventiva S.A stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -20.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Inventiva S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Inventiva S.A (2013–2024)

The table below shows the annual total liabilities of Inventiva S.A from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 €225.61 Million
≈ $263.77 Million
+122.08%
2023-12-31 €101.59 Million
≈ $118.77 Million
+44.04%
2022-12-31 €70.53 Million
≈ $82.45 Million
+112.96%
2021-12-31 €33.12 Million
≈ $38.72 Million
+19.53%
2020-12-31 €27.71 Million
≈ $32.39 Million
+77.98%
2019-12-31 €15.57 Million
≈ $18.20 Million
-14.54%
2018-12-31 €18.22 Million
≈ $21.30 Million
+75.86%
2017-12-31 €10.36 Million
≈ $12.11 Million
-21.15%
2016-12-31 €13.14 Million
≈ $15.36 Million
-26.22%
2015-12-31 €17.81 Million
≈ $20.82 Million
-17.67%
2014-12-31 €21.63 Million
≈ $25.28 Million
-23.05%
2013-12-31 €28.11 Million
≈ $32.86 Million
--

About Inventiva S.A

PA:IVA France Biotechnology
Market Cap
$1.05 Billion
€894.96 Million EUR
Market Cap Rank
#9525 Global
#147 in France
Share Price
€4.31
Change (1 day)
+2.50%
52-Week Range
€2.57 - €5.98
All Time High
€15.56
About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more